Ven-A-Care: How a Pharmacy Became a Drug-Pricing Whistleblower

Dey’s $280 million settlement over allegedly inflated drug prices was one result of Ven-A-Care’s work as a pharmaceutical whistleblower. The Key West home-infusion pharmacy brought False Claims Act cases from the buyer’s side of the transaction. The pharmacy knew the purchasing side. Its cases challenged the number on the reimbursement side. The alleged overpayment sat in the gap.

What Was Ven-A-Care?

Ven-A-Care of the Florida Keys was a home-infusion pharmacy founded in 1987 that became a corporate whistleblower in cases against multiple drug manufacturers. The business itself brought claims under the False Claims Act, alongside its principals. The Justice Department identified the pharmacy as the whistleblower in settlements involving both drug-price reporting and Medicaid rebates.

Ven-A-Care shows what a business can bring to a False Claims Act case as its relator, the party that files it on the government’s behalf: knowledge of the drugs and the transactions behind a government payment. The business itself was the whistleblower. The company supplying its drugs also supplied a number used to decide how much public health care programs would pay for them.

The pharmacy’s campaign reached federal and state claims. The United States joined claims against Abbott, Dey and Roxane, while Ven-A-Care pursued claims against other manufacturers without the government joining. The pricing information reached beyond a single manufacturer or a single public program.

How the Drug-Price Spread Worked

Average wholesale price was a published benchmark used in drug reimbursement. In the alleged pricing schemes, manufacturers reported inflated prices to drug-pricing publications, sold the drugs for less, and promoted the difference as a financial reason to buy their products.

The spread connected the sale to the public payment. A pharmacy or physician could buy at the lower price while receiving reimbursement calculated from the higher published number. Manufacturers allegedly used that spread to win customers. Medicare and Medicaid paid the inflated reimbursement, at taxpayers’ expense.

An Average That Did Not Measure the Transaction

Average wholesale price started as a markup over wholesale acquisition cost. A federal court’s account described how that markup stopped reflecting actual wholesaler margins as the market changed. The Centers for Medicare and Medicaid Services did not set the published prices. It entrusted manufacturers to report them accurately to the pricing publications.

The seller supplied the number, and the public program used it to pay the seller’s customer. The number could look like a market measurement while coming from the business that benefited from the sale.

Medi-Span’s pricing policy makes the distinction explicit. Its published average wholesale price is not an average of actual wholesale transactions. The publisher relies on manufacturer reports and says it does not independently investigate whether those reports match marketplace purchase or sale prices. It may check who sent the number. It does not check whether anyone paid it.

The Spread Became a Sales Argument

In the Dey case, the government alleged that inflated reported prices created higher reimbursement and that Dey used the difference from actual selling prices to induce purchases. The commercial incentive was built into the comparison: a customer could see the acquisition price and the amount the program would reimburse.

This is why the pricing and sales records belong together. A reported benchmark describes the number. A sales pitch can show what the manufacturer wanted the customer to do because of it. The buyer’s purchase records connect that pitch to an actual transaction.

The Campaign Reached More Than One Manufacturer

Ven-A-Care’s cases produced a series of reported settlements across manufacturers, products and payment programs. The same pharmacy appeared across cases involving infusion products, respiratory drugs and Medicaid rebate reporting.

Early Drug-Pricing Settlements

Bayer’s 2001 drug-pricing agreement called for $14 million to the United States and participating states. Ven-A-Care was to receive 20% of the federal share.

GlaxoSmithKline’s 2005 settlement over Zofran and Kytril exceeded $150 million, with approximately $26 million reported for Ven-A-Care and its principals. The government alleged inflated reimbursement benchmarks and marketing of the resulting spread. It also alleged that GlaxoSmithKline encouraged pooling leftover Kytril from vials and additional billing.

Aventis agreed in 2007 to pay more than $190 million in the Anzemet pricing case, with approximately $32 million reported for Ven-A-Care.

Apothecon Was Part of a Broader Resolution

Bristol-Myers Squibb and its subsidiary Apothecon entered a civil resolution exceeding $515 million in September 2007. It covered pricing and marketing allegations, including inflated price reporting, kickbacks, Abilify promotion and Serzone best-price reporting.

Ven-A-Care brought pricing cases included in that agreement. The resolution covered seven whistleblower cases in all, with approximately $50 million reported collectively for the whistleblowers.

The Medicaid Rebate Case Used a Different Input

The October 2009 settlement with Mylan, UDL, AstraZeneca and Ortho McNeil totaled $124 million. Here, the alleged manipulation concerned the drug’s classification for Medicaid rebates.

The rebate program required larger rebates for innovator drugs than for non-innovator drugs. The government alleged that the companies sold innovator drugs made by other manufacturers but classified them as non-innovator drugs, reducing what they owed Medicaid.

The Justice Department said Ven-A-Care would receive approximately $10.8 million as its share of the recovery across those settlements. This case expands the pharmacy-whistleblower story beyond average wholesale price: a classification field could change a public program’s payment just as a reported price could.

Infusion Products and Respiratory Drugs

The December 2010 announcement covering Roxane, Abbott and B. Braun set out separate settlements. Roxane’s was $280 million. Abbott’s was $126.5 million. B. Braun’s was $14,744,000.

Abbott’s cases involved infusion products and antibiotics. B. Braun’s involved infusion fluids, nutritional solutions and other intravenous drugs. Roxane allegedly reported inflated prices for generic drugs and marketed the reimbursement spread.

The department reported approximately $88.4 million collectively for Ven-A-Care and its principals across those settlements.

Dey’s separate respiratory-drug settlement that December carried approximately $67.2 million for the pharmacy and its principals. The drugs included albuterol sulfate, cromolyn sodium and ipratropium bromide.

The State Claims Continued Across Manufacturers

Ven-A-Care also settled with Watson and Par. Par reported a $154 million settlement involving Ven-A-Care and claims from several states.

Sandoz also faced Texas state and federal claims. The pricing information a pharmacy in Florida held could reach what another state’s Medicaid program paid.

Why Pharmacy Purchasing Knowledge Matters

Pharmacy purchasing records can put an actual drug transaction beside the published benchmark and the reimbursement it helped produce. We connect those records with the decisions behind the reported price.

A purchasing employee may understand the acquisition side. Someone working with reimbursement may see how the benchmark changes the claim payment. A sales or pricing employee may know why the spread was emphasized to the customer. Those views meet at the same transaction, even when they sit in different businesses.

A later government complaint against Professional Compounding Centers of America shows how directly the alleged sales instruction could be expressed. In its 2021 complaint announcement, the department described alleged inflated ingredient prices and marketing of reimbursement margins to compounding pharmacies. The complaint alleged:

The alleged instruction connects management, the sales staff and the pharmacy customer. It shows the same sales incentive seen in Ven-A-Care’s pricing cases.

Can a Pharmacist Be a Whistleblower?

Yes. A pharmacist who owned a compounding pharmacy brought the case resolved in Medisca’s 2024 settlement. The government alleged inflated average wholesale price reporting for ingredients used by pharmacies billing TRICARE and federal workers’ compensation.

Medisca allegedly sold resveratrol for less than $2 per gram while reporting an average wholesale price of $777 per gram. The alleged inflation drove up bills to TRICARE and federal workers’ compensation. The pharmacy owner knew the customer’s side of the business. Like Ven-A-Care’s cases, the case connected pharmacy knowledge to a supplier’s reported pricing.

The State Outcomes Turned on the Payment Connection

Separate state average wholesale price cases produced different outcomes depending on what the state showed about its use of the reported prices.

In Mississippi’s case against Sandoz, the court found that the company intentionally reported fictitious prices unrelated to actual acquisition costs and advertised the discrepancy to pharmacies. The state relied on those reports to estimate what pharmacies paid. The court awarded compensation for Medicaid overpayments, alongside civil penalties and punitive damages.

Alabama’s case against Sandoz ended differently. In 2012, the state’s highest court reversed the judgment and ruled for Sandoz because Alabama knew the reported prices were not actual prices and had based reimbursement decisions on policy considerations instead.

For a pharmacy insider, the question is concrete: where did this reported number enter the reimbursement calculation? We work through that connection with the people who understand the purchasing and payment records.

The Payment Benchmark Changed

Published prices once drove much of Medicaid’s drug reimbursement. The Health and Human Services Inspector General’s July 2011 report on replacing average wholesale price found that 45 states used it to estimate acquisition costs in the first quarter of that year.

Public Citizen’s 2018 study of pharmaceutical industry settlements found that overcharging government health programs appeared in 204 settlements from 1991 through 2017, more than any other violation category it examined. Its explanation puts the state payment system at the center:

The study described the move toward actual acquisition cost as a change that could reduce the opportunity for average wholesale price fraud. The Centers for Medicare and Medicaid Services explained that artificially inflated published prices had caused states to overpay for drug ingredients. Its National Average Drug Acquisition Cost benchmark drew on pharmacy purchase data.

Average wholesale price also survived in specified payment settings. The agency’s July 2026 Medicare Part B payment file still used it for certain vaccines, blood products and COVID-19 treatments. For healthcare insiders, the program, product and payment period determine which benchmark matters. Ven-A-Care’s history gives an insider a useful question to bring us: does the number driving reimbursement reflect the transaction the business actually made?

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Ven-A-Care’s reported awards show how valuable a pharmacy business’s knowledge can become when it exposes a government-payment problem.

Bring Us the Pricing Connection

If your pharmacy’s acquisition and reimbursement records tell different stories about the same drug, speak with our whistleblower experts about the pricing behind those payments. We build your strongest case with you around the transactions, reported prices and decisions that moved government money, and bring in pharmaceutical pricing whistleblower lawyers who understand those connections. We stay beside you from the first assessment through the case.